Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer

Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUVmax, no variable was predictive at P < 0.05. When FDG SUVmax was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02, 0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.

[1]  H. Lyng,et al.  Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis , 2000, British Journal of Cancer.

[2]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  A. Fyles,et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  M. Muzi,et al.  Analyzing the results of 18FMISO PET hypoxia imaging What is the best way to quantify hypoxia , 2002 .

[5]  J. M. Ollinger,et al.  Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.

[6]  P Kumar,et al.  Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. , 2000, Seminars in hematology.

[7]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[8]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Krohn,et al.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.

[10]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[11]  L. Peters,et al.  Targeting Hypoxia in Head and Neck Cancer , 2001, Acta oncologica.

[12]  R. Wahl,et al.  Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. , 1996, Nuclear medicine and biology.

[13]  L. Dubois,et al.  Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry , 2004, British Journal of Cancer.

[14]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[15]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[16]  J. Rasey,et al.  Positron emission tomography. A new tool for characterization of malignant disease and selection of therapy. , 1994, Acta oncologica.

[17]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  J. Chapman,et al.  The detection and measurement of hypoxic cells in solid tumors , 1984, Cancer.

[19]  D. Mankoff,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by ( 18 F)Fluoromisonidazole and ( 18 F)Fluorodeoxyglucose Positron , 2004 .

[20]  M Molls,et al.  Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[21]  J. Brown,et al.  Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. , 2000, Molecular medicine today.

[22]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[23]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[25]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[26]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[27]  J. Rasey,et al.  Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. , 1990, Radiation research.

[28]  C. Stearns,et al.  Investigation of the count rate performance of the General Electric Advance positron emission tomograph , 1994, Proceedings of 1994 IEEE Nuclear Science Symposium - NSS'94.

[29]  Michael J. Welch,et al.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Kenneth A Krohn,et al.  Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.

[31]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  C. Mathis,et al.  A radiosynthesis of fluorine-18 fluoromisonidazole. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[34]  D A Bloch,et al.  Tissue oxygen distribution in head and neck cancer patients , 1999, Head & neck.

[35]  George Fountzilas,et al.  Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. , 2004, International journal of radiation oncology, biology, physics.

[36]  Andreas Dietz,et al.  Predictive Value of the Tumor Oxygenation by Means of pO2 Histography in Patients with Advanced Head and Neck Cancer , 2001, Strahlentherapie und Onkologie.

[37]  Michael H. Kutner.  Applied Linear Statistical Models , 1974 .